About Roche
Roche is a venture capital firm founded in 1896. It is primarily based out of Basel, Switzerland. As of Nov 2021, Roche has invested in 74 companies. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Series A round of GlycoEra Overall, Roche portfolio has seen 1 unicorn, 21 IPOs and 34 acquisitions including key companies like Flatiron Health, Horizon Discovery and Ideaya Biosciences. A lot of funds co-invest with Roche, with names like SR One sharing a substantial percentage of its portfolio. Roche has team of 3 people including 1 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 4 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Unicorns
Portfolio Soonicorns
Roche's List of Top Investments
Roche has a portfolio of 74 companies, one of which is a Unicorn. Their most notable investments are in MacuLogix and Mission Therapeutics.Their portfolio spans across United States, Canada, Italy and 10 more locations. They have invested in Life Sciences, High Tech, HealthTech and 3 other sectors, across stages such as Series A, Series B and 4 more. Here is the list of top investments by Roche:Cloud-based practice management tool for providers. The company's OncologyCloud platform includes the electronic medical record for oncology, an analytics section for business clinical intelligence, a patient portal, and integrated billing management which allows cancer care providers and life sciences companies to track metrics related to cancer care, match patients to clinical trials and automate data collection.
Key facts about Flatiron Health
- Founded Year: 2012
- Location: New York City (United States)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $314M
- Employee Count: 1,449 as on May 31, 2026
- Investors: Allen & Company, Google Ventures and 27 Others
- Latest Funding Round: Series C, Jan 06, 2016, $*****
- Highlight: Acquired
Developer of cell lines with genetic modification using AAV gene-editing platform. The company has cell line engineering, knockout cell lines, and reporter cell lines. It also provides services in T cell activation assay, lymphocyte reaction assay, T cell-mediated tumor cell lysis assay, ADCC, and CDC assays, gene-editing for immuno-oncology, CRISPR Screening, drug combination screening, in vitro assay, and in-vivo assay.
Key facts about Horizon Discovery
- Founded Year: 2007
- Location: Cambridge (United Kingdom)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $46.3M
- Employee Count: 94 as on Apr 30, 2026
- Investors: ValueAct Capital, Draper Esprit and 13 Others
- Latest Funding Round: Post IPO, Sep 07, 2018, $*****
- Highlight: Acquired
Developer of oncology-focused precision medicine using molecular diagnostics. The lead candidate IDE196 is a protein kinase C an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. Others include PARG, WRN, poltheta, Darovasertib, and others.
Key facts about Ideaya Biosciences
- Founded Year: 2015
- Location: San Francisco (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $157M
- Employee Count: 261 as on May 31, 2026
- Investors: BVF Partners, Boxer Capital and 15 Others
- Latest Funding Round: Post IPO, Aug 04, 2020, $*****
- Highlight: Public
Developer of selective kinase inhibitors for patients with genomically defined cancers. Their approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Their ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets.
Key facts about Blueprint Medicines
- Founded Year: 2008
- Location: Cambridge (United States)
- Annual Revenue: $500M - $1B as on Dec 31, 2024
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $115M
- Employee Count: 728 as on May 31, 2026
- Investors: Foresite Capital, BVF Partners and 20 Others
- Latest Funding Round: Post IPO, Jun 30, 2022, $*****
- Highlight: Acquired
Developer of small molecule drugs for treating cancer. Its Degronimid platform incorporates highly selective small-molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural proteasome system. It has developed CFT7455 for treating hematologic malignancies, CFT8634 for sarcoma, BRAF V600E for slid tumors.
Key facts about C4 Therapeutics
- Founded Year: 2016
- Location: Cambridge (United States)
- Annual Revenue: $10M - $50M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $223M
- Employee Count: 111 as on May 31, 2026
- Investors: HTIF, HBM Healthcare Investments and 27 Others
- Latest Funding Round: Post IPO, Jan 04, 2024, $*****
- Highlight: Public
Roche's Year-on-Year Investment Trends
Roche has invested in 74 companies over the last 22 years, with an average of 2 new investments annually in the last 10 years. Its most recent first time investment was in GlycoEra and most recent follow-on round was in Vaxcyte.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 0 | 0 | 0 |
2024 | 0 | 0 | 0 |
2023 | 0 | 0 | 0 |
2022 | 0 | 0 | 0 |
2021 | 2 | 0 | 2 |
2020 | 1 | 2 | 3 |
2019 | 1 | 3 | 4 |
2018 | 7 | 1 | 8 |
2017 | 4 | 2 | 6 |
Roche's Investments by Stage
Roche has made 18 investments in Series A stage with an average round size of $37.6M, 18 investments in Series B stage with an average round size of $32.7M and 5 investments in Series C stage with an average round size of $119M.Stage of entry | No. of Investments |
|---|---|
Series A | 18 |
Series B | 18 |
Series C | 5 |
Series D | 3 |
Post IPO | 2 |
Others | 1 |
Note: We have considered here, only first round of investments
Roche's Investments by Sector
Roche has a diverse portfolio, with companies operating in the Life Sciences, High Tech, HealthTech, Enterprise Applications and Sustainability Tech. Notably, it has invested in 66 Tech companies, 65 Enterprise (B2B) companies, 11 Software companies and at least 6 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 42 |
High Tech | 14 |
HealthTech | 7 |
Enterprise Applications | 5 |
Sustainability Tech | 5 |
Others | 6 |
Note: We have considered here, only first round of investments
Roche's Investments by Geography
Roche has made most investments in United States (38), followed by United Kingdom where it has made 2 investments.Country | No. of Investments |
|---|---|
United States | 38 |
United Kingdom | 2 |
Austria | 1 |
Denmark | 1 |
France | 1 |
Others | 4 |
Note: We have considered here, only first round of investments
Roche's recent investments
Roche has not made any investment in 2026 so far.Here are the most recent investments by Roche:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Nov 05, 2021 | Switzerland | Series A | 3552 | [+2] | |
Jan 28, 2021 | Italy | Series A | 3401 | [+3] | |
Aug 26, 2020 | United States | Series C | 5815 | [+20] | |
Apr 03, 2020 | United States | Series D | 6177 | ||
Jan 10, 2020 | United States | Series B | 1037 | [+6] |
Unicorns in Roche's Portfolio
Roche has 1 unicorn in its portfolio - Freenome Health. The most recent unicorn in their portfolio is Freenome Health which became a unicorn in 2022, 1 years after Roche first invested in it.Here is a list of unicorns in Roche's portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
66 | Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | - | Series E | joqjre{ |
IPOs and Publicly Listed companies in Roche's Portfolio
21 of Roche's portfolio companies have become public. Entrada Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Oct 2021 at marketcap of $598M and TEMPEST THERAPEUTICS got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ).Here are Roche's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Oct 29, 2021 | Dec 22, 2018 | Series A | 5945 | |
Jun 16, 2021 | - | - | 2965 | |
Oct 16, 2020 | 2018 | Series A | 6843 | |
Oct 02, 2020 | Jan 07, 2016 | Series A | 3284 | |
Jun 12, 2020 | Jul 23, 2015 | Series A | 8532 |
Acquired companies in Roche's Portfolio
34 companies from Roche's portfolio have been acquired. The most recent acquisition was Complete Genomics in Feb 2026 by Swiss Rockets for $*****.Here are Roche's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Feb 23, 2026 | - | - | 5981 | |
Jun 02, 2025 | - | - | 7413 | |
Apr 16, 2025 | Jun 08, 2016 | Series B | 5616 | |
Jan 13, 2025 | Nov 14, 2017 | Series D | 9814 | |
Jan 08, 2024 | Jul 05, 2006 | Series C | 6806 |
Team profile of Roche
Roche has a team of 3 members including 1 Partner and 2 Principals located in Switzerland. Roche's team does not sit on the board of any company as of now.Here is a list of all team members in Roche:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | - | - | - | |
Principal | Basel | - | - | |
Principal | Basel | - |
Co-investors of Roche
Over the past 22 years, 380 investors have co-invested in Roche's portfolio companies. This includes funds and angels.
- Invested before Roche: HHS, Google Ventures and 116 others have invested in rounds before Roche. There are 6 companies where HHS has invested before Roche and 3 companies where Google Ventures has invested before Roche.
- Top Co-investors of Roche: 121 investors entered a company along with Roche. These include investors like SR One (6 companies).
- Invested after Roche: A total of 141 investors have invested in Roche's portfolio after their investments. Top Investors include Roche (7 companies), Adage Capital Management (4 companies) and RA Capital Management (4 companies).
Recent News related to Roche
•
Aligos Therapeutics Closes $125M Series B FinancingGlobeNewswire•Jan 10, 2020•Wellington, Janus Henderson Investors, Boxer Capital, Pivotal bioVenture Partners China and 6 others
•
•
Venture Capital Access Online | Venture Capital NewsVCA Online•Dec 18, 2018•Entrada Therapeutics, 5AM Ventures, Roche, MRLV and 1 other
•
•
Biodesy Announces New CEO and $20 Million Series C Financing to Accelerate Expansion into Biotherapeutics Discovery and Development MarketBusiness Wire•Sep 10, 2018•Alexandria, Roche, Pfizer, 5AM Ventures and 1 other
•
Roche Appoints James Sabry As Global Head Of Partnering, Effective August 1Rttnews•Jun 22, 2018•Roche
•
Cipla ties up with Roche to sell 2 cancer drugs in IndiaIndiatimes•Feb 27, 2018•Cipla, Roche, Roche Products, Roche and 1 other
•
•
Roche and Ignyta Reach Definitive Merger AgreementBusiness Wire•Dec 21, 2017•Roche, Ignyta, Roche, Roche Products
•
Confo Therapeutics enters into Drug Discovery Collaboration with RochePharma Journalist•Dec 19, 2017•Roche, Confo Therapeutics, Roche
